{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:58:59Z","timestamp":1787979539435,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T00:00:00Z","timestamp":1451952000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"no funder"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00277-015-2578-6","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T05:02:13Z","timestamp":1451970133000},"page":"417-423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma"],"prefix":"10.1007","volume":"95","author":[{"given":"L.","family":"Strobbe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. L. F. G.","family":"Valke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. J.","family":"Diets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"van den Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Aben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M. M.","family":"Raemaekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"Hebeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. J. M.","family":"van Krieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,5]]},"reference":[{"key":"2578_CR1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","volume":"17","author":"V Diehl","year":"1999","unstructured":"Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E, Poppema S, Harris M, Franssila K, van Krieken J, Marafioti T, Anagnostopoulos I, Stein H (1999) Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin\u2019s disease and lymphocyte-rich classical Hodgkin\u2019s disease: report from the European task force on lymphoma project on lymphocyte-predominant Hodgkin\u2019s disease. J ClinOncol 17:776\u2013783","journal-title":"J ClinOncol"},{"key":"2578_CR2","volume-title":"Hodgkin lymphoma. WHO classification of tumours of haematopoietic and lymphoid tissues","author":"HPS Stein","year":"2008","unstructured":"Stein HPS, Delsol G (2008) Hodgkin lymphoma. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon"},{"key":"2578_CR3","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2003-02-0626","volume":"102","author":"L Boudova","year":"2003","unstructured":"Boudova L, Torlakovic E, Delabie J, Reimer P, Pfistner B, Wiedenmann S, Diehl V, Muller-Hermelink HK, Rudiger T (2003) Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell\/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell\/histiocyte-rich B-cell lymphoma. Blood 102:3753\u20133758","journal-title":"Blood"},{"key":"2578_CR4","first-page":"1889","volume":"96","author":"I Anagnostopoulos","year":"2000","unstructured":"Anagnostopoulos I, Hansmann ML, Franssila K, Harris M, Harris NL, Jaffe ES, Han J, van Krieken JM, Poppema S, Marafioti T, Franklin J, Sextro M, Diehl V, Stein H (2000) European task force on lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 96:1889\u20131899","journal-title":"Blood"},{"key":"2578_CR5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361\u20131392","journal-title":"Blood"},{"key":"2578_CR6","first-page":"354","volume":"53","author":"EA Hawkes","year":"2012","unstructured":"Hawkes EA, Wotherspoon A, Cunningham D (2012) The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management. LeukLymphoma 53:354\u2013361","journal-title":"LeukLymphoma"},{"key":"2578_CR7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1634\/theoncologist.2009-0099","volume":"14","author":"AI Lee","year":"2009","unstructured":"Lee AI, LaCasce AS (2009) Nodular lymphocyte predominant Hodgkin lymphoma. Oncologist 14:739\u2013751","journal-title":"Oncologist"},{"key":"2578_CR8","doi-asserted-by":"crossref","unstructured":"Nogova L, Rudiger T, Engert A (2006) Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematology \/ the Education Program of the American Society of Hematology American Society of Hematology Education Program:266-272.","DOI":"10.1182\/asheducation-2006.1.266"},{"key":"2578_CR9","first-page":"1920","volume":"52","author":"K Farrell","year":"2011","unstructured":"Farrell K, McKay P, Leach M (2011) Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network. LeukLymphoma 52:1920\u20131928","journal-title":"LeukLymphoma"},{"key":"2578_CR10","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1182\/blood-2013-07-453241","volume":"122","author":"RH Advani","year":"2013","unstructured":"Advani RH, Hoppe RT (2013) How I treat nodular lymphocyte predominant Hodgkin lymphoma. Blood 122:4182\u20134188","journal-title":"Blood"},{"key":"2578_CR11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","volume":"111","author":"H Schulz","year":"2008","unstructured":"Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rudiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M (2008) Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 111:109\u2013111","journal-title":"Blood"},{"key":"2578_CR12","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","volume":"101","author":"BC Ekstrand","year":"2003","unstructured":"Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, Natkunam Y, Bartlett NL, Horning SJ (2003) Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 101:4285\u20134289","journal-title":"Blood"},{"key":"2578_CR13","doi-asserted-by":"crossref","first-page":"198A","DOI":"10.1182\/blood.V110.11.644.644","volume":"110","author":"SJ Horning","year":"2007","unstructured":"Horning SJ, Bartlett NL, Breslin S, Advani RH, Hoppe RT, Ekstrand BC, Lucas JB (2007) Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin\u2019s disease (NLPHD). Blood 110:198A\u2013198A","journal-title":"Blood"},{"key":"2578_CR14","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","volume":"21","author":"BM Aleman","year":"2003","unstructured":"Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van\u2019t Veer MB, Bartelink H, van Leeuwen FE (2003) Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease. J Clin Oncol : Off J Am Soc Clin Oncol 21:3431\u20133439","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"2578_CR15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","volume":"28","author":"M Al-Mansour","year":"2010","unstructured":"Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ (2010) Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin\u2019s lymphoma. J ClinOncol 28:793\u2013799","journal-title":"J ClinOncol"},{"issue":"Suppl 5","key":"2578_CR16","first-page":"v168","volume":"21","author":"A Engert","year":"2010","unstructured":"Engert A, Eichenauer DA, Dreyling M (2010) Hodgkin\u2019s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 1. AnnOncol 21(Suppl 5):v168\u2013v171","journal-title":"AnnOncol"},{"key":"2578_CR17","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"DDV Hasenclever","year":"1998","unstructured":"Hasenclever DDV (1998) A prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced Hodgkin\u2019s disease. NEnglJMed 339:1506\u20131514","journal-title":"NEnglJMed"},{"key":"2578_CR18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","volume":"116","author":"I Biasoli","year":"2010","unstructured":"Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F, Coiffier B, Bosly A, Divine M, Brice P (2010) Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the adult lymphoma study group. Cancer 116:631\u2013639","journal-title":"Cancer"},{"key":"2578_CR19","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1200\/JCO.2005.17.970","volume":"23","author":"AHH Shimabukuro-Vornhagen","year":"2005","unstructured":"Shimabukuro-Vornhagen AHH, Engert A, Balleisen L, Majunke P, Heil G, Eich HT, Stein H, Diehl V, Josting A (2005) Lymphocyte-rich classical Hodgkin\u2019s lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin\u2019s Study Group trials. J Clin Oncol: Off J Am Soc Clin Oncol 23:5739\u20135745","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2578_CR20","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","volume":"118","author":"DA Eichenauer","year":"2011","unstructured":"Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Boll B, von Tresckow B, Nogova L, Borchmann P, Engert A (2011) Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 118:4363\u20134365","journal-title":"Blood"},{"key":"2578_CR21","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","volume":"32","author":"RH Advani","year":"2014","unstructured":"Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y, Bartlett NL (2014) Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol: Off J Am Soc Clin Oncol 32:912\u2013918","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2578_CR22","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.2014.60.4363","volume":"33","author":"DA Eichenauer","year":"2015","unstructured":"Eichenauer DA, Plutschow A, Fuchs M, von Tresckow B, Boll B, Behringer K, Diehl V, Eich HT, Borchmann P, Engert A (2015) Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. J Clin Oncol: Off J Am Soc Clin Oncol 33:2857\u20132862","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2578_CR23","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.ijrobp.2008.09.049","volume":"74","author":"RLGT Haas","year":"2009","unstructured":"Haas RLGT, Aleman BM, Henry-Amar M, de Boer JP, de Jong D (2009) Low-dose involved-field radiotherapy as alternative treatment of nodular lymphocyte predominance Hodgkin\u2019s lymphoma. Int J Radiat Oncol, Biol, Phys 74:1199\u20131202","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"key":"2578_CR24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","volume":"28","author":"RC Chen","year":"2010","unstructured":"Chen RC, Chin MS, Ng AK, Feng Y, Neuberg D, Silver B, Pinkus GS, Stevenson MA, Mauch PM (2010) Early-stage, lymphocyte-predominant Hodgkin\u2019s lymphoma: patient outcomes from a large, single-institution series with long follow-up. JClinOncol 28:136\u2013141","journal-title":"JClinOncol"},{"key":"2578_CR25","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1093\/annonc\/mds201","volume":"23","author":"WB Stevens","year":"2012","unstructured":"Stevens WB, van Krieken JH, Mus RD, Arens AI, Mattijssen V, Oosterveld M, de Kruijf EJ, de Vries F, Koster A, van der Maazen R, Raemaekers J (2012) Centralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed Hodgkin lymphoma. Ann Oncol: Off J Eur Soc Med Oncol \/ ESMO 23:2676\u20132681","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol \/ ESMO"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2578-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2578-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2578-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T14:49:21Z","timestamp":1600008561000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2578-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["2578"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2578-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,5]]}}}